Navigation Links
Chiltern Is a Nominee on the SCRIP CRO of the Year Award Shortlist
Date:10/27/2008

LONDON, Oct. 28 /PRNewswire/ -- Chiltern, a leading global clinical research organization, announced that it is a nominee on this year's shortlist for the SCRIP Awards in the "Best Contract Research Organization" category. The winners will be announced at the fourth annual SCRIP awards ceremony on December 10, at the London Hilton on Park Lane.

"I am delighted that Chiltern made the shortlist for this esteemed award," commented Glenn Kerkhof, Chiltern's CEO. "This nomination provides recognition for the overall achievements that Chiltern and its employees have accomplished during this past year."

The SCRIP awards comprise 13 categories, and an independent panel of industry experts reviews the categories most relevant to their expertise ensuring objectivity and credibility. The "Best Contract Research Organization" category looks at six criteria ranging from exceeding sponsor expectations to the incorporation of novel technologies.

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad therapeutic range for a wide variety of clients. Chiltern employs over 1,300 people located in 23 offices throughout Europe, the Americas and Asia. Chiltern provides services including Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions.

For More Information Contact:

Catherine Lemercier Richard Baptista

Chiltern International, Inc. Chiltern International Ltd.

2111 Palomar Airport Road 171 Bath Road

Suite 200 Slough

Carlsbad Berkshire

CA 92011 SL1 4AA

USA UNITED KINGDOM

Tel: 1 (760) 707 5025 Tel: 44 (0) 1753 512 000

Fax: 1 (760) 707 5022 Fax: 44 (0) 1753 511 116

Email: Catherine.Lemercier@chiltern.com Email:

Richard.Baptista@chiltern.com


'/>"/>
SOURCE Chiltern
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Chiltern Early Phase: Fully Integrated and Business Ready
2. Pinnacle Biologics Announces Contract With Chiltern
3. RiskMetrics (ISS), An Independent Proxy Advisory Firm, Recommends Voting the GOLD Card for Four of PTVs Nominees: Anderson, McInerney, Melrose, and OHolla
4. Sigma-Aldrich Releases WTA2, a Transplex Whole Transcriptome Amplification Technology for Degraded RNA Samples
5. CFO of China Yingxia Emphasizes Growth in Organic and Health Food Segment in Interview by The Wall Street Transcript
6. iMedica Partners With LDM GROUP to Offer ScriptGuide to Physician Practice Customers
7. Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
8. The Wall Street Transcript Interviews AMDL, Inc. CEO & President Gary Dreher for Fall Healthcare Issue
9. Stem Cell Profits Five Years Away, Says Repair Stem Cell Institute Chairman to The Wall Street Transcript
10. RainDance and Scripps to Collaborate on Targeted Sequencing for Wellderly Study
11. Half of Surveyed Physicians Expect to Replace Between 6 Percent and 15 Percent of Their Sustiva Prescriptions with Isentress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... N.J. , Dec. 8, 2016  Soligenix, ... late-stage biopharmaceutical company focused on developing and commercializing ... an unmet medical need, announced today the long-term ... with SGX942 (dusquetide), a first-in-class Innate Defense Regulator ... in head and neck cancer patients undergoing chemoradiation ...
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
(Date:12/8/2016)... South Korea , Dec. 8, 2016 ... a $21 billion KRW (US $18.9M) Series A financing. ... Kolon Investment, G.N. Tech Venture and SNU Bio Angel. ... Eutilex to 30.5 billion KRW (US $27.7M) since its ... help Eutilex to bolster the development and commercialization of ...
(Date:12/8/2016)... 8, 2016   Biocept, Inc . (NASDAQ: ... of clinically actionable liquid biopsy tests to improve ... data featuring its Target Selectorâ„¢ Circulating Tumor Cell ... the detection of actionable biomarkers in patients with ... by Sara Cannon Research Institute (SCRI), the research ...
Breaking Biology Technology:
(Date:11/15/2016)... Research and Markets has announced the addition of the "Bioinformatics ... ... The global bioinformatics market is projected ... in 2016, growing at a CAGR of 21.1% during the forecast ... by the growing demand for nucleic acid and protein sequencing, increasing ...
(Date:6/27/2016)... June 27, 2016 Research and Markets has ... 2016-2020" report to their offering. ... America to grow at a CAGR of 12.28% during ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:6/22/2016)... 22, 2016 On Monday, the Department of ... to share solutions for the Biometric Exit Program. The ... Border Protection (CBP), explains that CBP intends to add ... the United States , in order to ... imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):